PharmEnable Therapeutics

PharmEnable is a biopharmaceutical company based in Cambridge, UK, founded in 2016. The company's slogan "Harnessing the power of chemical novelty, diversity and 3-dimensionality to develop innovative small molecule drugs" reflects its focus on utilizing AI to discover effective small-molecule medicines for disease targets that are inaccessible to antibodies. PharmEnable's proprietary AI-enabled drug discovery platform, chemSEEK, enables the exploration of new chemical spaces and the discovery of novel small molecules with antibody-like specificity and selectivity. With an initial focus on oncology and neurology, PharmEnable is developing a pipeline of wholly owned therapeutics. Besides, the company engages in drug discovery partnerships across a range of disease areas where accessing the target poses a significant challenge. As a spinoff of the University of Cambridge, it benefits from its academic roots. In May 22, 2023, PharmEnable successfully secured a £6.00M Seed Round investment from a group of notable investors, including Parkwalk Advisors, Martlet Capital, MP Healthcare Venture Management, Wren Capital LLP, o2h Ventures, University of Cambridge Enterprise, Jonathan Milner, Arrowfield Capital, Heyford Trust. This investment indicates confidence from experienced investors in the company's innovative approach and potential in revolutionizing small molecule therapeutics through AI. To learn more about PharmEnable, visit their website at pharmenabletx.com and connect with them on LinkedIn.